3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
padeliporfin
5
Nivolumab
5
Ipilimumab
4
Sunitinib
3
Specimen Handling
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Abiraterone Acetate
3
pembrolizumab
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
abiraterone
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Pluvicto
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
vinflunine
1
valrubicin
1
tislelizumab
1
temsirolimus
1
sipuleucel-T
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Rivaroxaban
×
Genitourinary
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled